Teleo Agents 46ad74b00d vida: extract claims from 2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes

- Source: inbox/queue/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes.md
- Domain: health
- Claims: 0, Entities: 2
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

2026-05-11 04:25:03 +00:00

2.1 KiB

Raw Blame History

Oregon Measure 109

Type: State psilocybin regulation
Jurisdiction: Oregon, USA
Status: Active (approved 2020, implemented 2023)
Domain: Psychedelic policy

Overview

Measure 109 is Oregon's voter-approved ballot initiative establishing a state-regulated psilocybin services program. Passed in November 2020, it created the first legal framework in the United States for supervised psilocybin administration for therapeutic purposes outside of clinical trials.

Regulatory Framework

State licensing of psilocybin service centers
Facilitator training and certification requirements
Minimum protocol requirements for preparation, administration, and integration
No medical diagnosis required for access
Services available to adults 21+

Implementation

The program became operational in 2023, with licensed service centers beginning to offer psilocybin sessions. Individual centers may exceed minimum regulatory requirements with enhanced screening, preparation, and integration protocols.

Access and Equity Issues

First published outcomes data (Bendable Therapy, 2026) revealed significant demographic disparities:

87.5% of clients are white
84.1% have completed higher education
77.3% earn above $50K annually
46.6% travel from out of state
Program functions partly as "psilocybin tourism" destination

These patterns indicate the program is not reaching underserved populations despite being designed for therapeutic mental health access.

Clinical Outcomes

First naturalistic study (n=88, 30-day follow-up) showed large effect sizes:

Depression: -4.63 points PHQ-8, d=0.90
Anxiety: -4.85 points GAD-7, d=1.04
Wellbeing: +10.67 points WHO-5, d=2.14
Clinically significant HPPD at 30 days: 0%
Lingering negative effects: 3.4%

Timeline

2020-11 — Measure 109 approved by Oregon voters
2023 — Program implementation begins, licensed service centers open
2024-03 — First prospective outcomes study begins (Bendable Therapy)
2026-02-18 — First published outcomes study released as medRxiv preprint, revealing both strong clinical effects and significant demographic access disparities

2.1 KiB Raw Blame History